Contact Information

Call us at: (614) 355-3171

Fax us at: (614) 722-3273

Email Liubov V. Gushchina, MSc, PhD

Center for Gene Therapy700 Children’s DriveColumbus, OH 43205 (map)

Learn more about Liubov V. Gushchina

Research

Lab(s)

Center for Gene Therapy

Dr. Gushchina pursued her doctorate in Molecular Biology at the Institute of Protein Research of the Russian Academy of Science, where she developed skills in proteomics, molecular biology, biochemistry and biophysics and worked to advance understandings of protein folding and how to manipulate protein structures to enable the creation of novel therapeutics. During her postdoctoral training at The Ohio State University under the supervision of Noah Weisleder, PhD, and in collaboration with Ling-Qun Hu, MD, Dr. Gushchina developed an effective approach to prepare pluripotent stem cells (PSCs) for implantation to treat myocardial infarction and other degenerative diseases. She also investigated the role of tripartite motif (TRIM) family proteins in facilitating membrane repair capacity in striated muscle cells and lung cell regeneration after injury, work that led to the development of the MG53 protein-based therapy to treat limb-girdle muscular dystrophy type R2 (LGMDR2 or LGMD2B/dysferlinopathy) and TRIM family constructs for adeno-associated virus vector-based gene therapy treatments. As a Research Scientist in the lab of Kevin Flanigan, MD, at the Center for Gene Therapy at Nationwide Children’s Hospital, Dr. Gushchina developed a U7snRNA-based exon skipping platform to treat Duchenne Muscular Dystrophy (DMD) as well as gene replacement therapy for Limb-Girdle Muscular Dystrophy type R7 (LGMDR7). Publications

                  Gushchina LV, Vetter TA, Frair EC, Bradley AJ, Grounds KM, Lay JW, Huang N, Suhaiba A, Schnell FJ, Hanson G, Simmons TR, Wein N, Flanigan KM. Systemic PPMO-mediated dystrophin expression in the Dup2 mouse model of Duchenne muscular dystrophy. Mol Ther Nucleic Acids. 2022 Dec 13; 30: 479-492.

                


                  Wein N, Vetter TA, Vulin A, Simmons TR, Frair EC, Bradley AJ, Gushchina LV, Almeida CF, Huang N, Lesman D, Rajakumar D, Weiss RB, Flanigan KM. Systemic delivery of an AAV9 exon-skipping vector significantly improves or prevents features of Duchenne muscular dystrophy in the Dup2 mouse. Mol Ther Methods Clin Dev. 2022 Sep 8; 26: 279-293.

                


                  Wein N, Dunn DM, Waldrop MA, Gushchina LV, Frair EC, Weiss RB, Flanigan KM. Absence of Significant Off-Target Splicing Variation with a U7snRNA Vector Targeting DMD Exon 2 Duplications. Hum Gene Ther. 2021 Nov; 32: 1346-1359.

                


                  Gushchina LV, Frair EC, Rohan N, Bradley AJ, Simmons TR, Chavan HD, Chou HJ, Eggers M, Waldrop MA, Wein N, Flanigan KM. Lack of Toxicity in Nonhuman Primates Receiving Clinically Relevant Doses of an AAV9.U7snRNA Vector Designed to Induce DMD Exon 2 Skipping. Hum Gene Ther. 2021 Sep; 32: 882-894.

                


                  Gushchina LV, Kwiatkowski TA, Bhattacharya S, Weisleder NL. Conserved structural and functional aspects of the tripartite motif gene family point towards therapeutic applications in multiple diseases. Pharmacol Ther. 2018 May; 185: 12-25.

                


                  Gushchina LV, Bhattacharya S, McElhanon KE, Choi JH, Manring H, Beck EX, Alloush J, Weisleder N. Treatment with Recombinant Human MG53 Protein Increases Membrane Integrity in a Mouse Model of Limb Girdle Muscular Dystrophy 2B. Mol Ther. 2017 Oct 4; 25: 2360-2371.

View More Publications

Biography

Liubov V. Gushchina, MSc, PhD, is a Principal Investigator in the Center for Gene Therapy at the Abigail Wexner Research Institute at Nationwide Children’s Hospital, and Research Assistant Professor in the Department of Pediatrics at the Ohio State University College of Medicine. Dr. Gushchina is an experienced biochemist, molecular biologist and gene therapy specialist.

Academic and Clinical Areas

Center for Gene Therapy

Principal Investigator

Primary Department

Center for Gene Therapy

Awards, Honors & Organizations

Elsevier Prizes for Best Oral or Poster Presentation, 26th International Annual Congress of the World Muscle Society (WMS), 2021 Best Poster, The Dorothy M. Davis Heart & Lung Research Institute, The Ohio State University, USA, 2016 AHA Postdoctoral Fellowship Award, The American Heart Association (Great Rivers Affiliate), USA, 2016 Distinguished Post-Doctoral Award, The Dorothy M. Davis Heart & Lung Research Institute, The Ohio State University, USA, 2014 Muscle Group Postdoctoral Fellowship Award, The Internal Muscle Health and Neuromuscular Disorders Program, NCH/OSU, USA, 2014 Official Thanks, Governor of Moscow Region, Russia, 2011 Grant, Young Scientists of President of the Russian Federation, Russia, 2011 Short-Term Fellowship of European Molecular Biology Organization (EMBO), The Institute for Biophysical Chemistry at the Goethe University in Frankfurt am Main, Germany, 2010 Award for Young Scientists for the Best Research, Institute of Protein Research, RAS, Russia, 2009 Youth Travel Fund of Federation of European Biochemical Societies (FEBS), The FEBS Workshop “Protein Modules and Networks in Health and Disease”, Austria, 2009 Youth Travel Fund of Federation of European Biochemical Societies (FEBS), The FEBS Workshop “The Biology of Modular Protein Domains”, Austria, 2007, 2007 Youth Travel Fund of Federation of European Biochemical Societies (FEBS), The FEBS Advanced Course “Advanced Methods in Macromolecular Crystallization II”, Czech Republic, 2006 Member, World Muscle Society (WMS), 2019 - Present Member, American Society of Gene & Cell Therapy (ASGCT), 2019 - Present Member, National Center for Faculty Development and Diversity, 2017 - Present Member, Sigma Xi, 2016 - 2017 International Committee Member, OSU Postdoc Association (PDA), 2015 - Present Member, American Physiological Society (APS), 2015 - 2018 Member, Federation of European Biochemical Societies (FEBS) (Moscow Branch), 2013 - Present Member, American Heart Association (AHA), 2012 - Present Member, American Society for Nutrition (ANS), 2012 - 2016

Education

Post Doctoral

The Ohio State University

Date Completed: 06/30/2017

Graduate School

Institute of Protein Research of the Russian Academy of Science

Date Completed: 03/26/2009

Undergraduate School

M. V. Lomonosov Moscow State University

Date Completed: 06/21/2005

Professional Experience

2017 - 2022 Nationwide Children’s Hospital, Research Scientist/Sr. Research Scientist2011 - 2017 The Ohio State University, Postdoctoral Scientist2010 - 2010 Institute of Biophysical Chemistry, Goethe University in Frankfurt am Main, Invited Investigator

Contact Information

Center for Gene Therapy

Call us at: (614) 355-3171

Fax us at: (614) 722-3273

Email Liubov V Gushchina

                    700 Children's DriveColumbus, OH 43205 (map)

Connect with Liubov V. Gushchina

Connect on LinkedIn

Contact Information

Call us at: (614) 355-3171

Fax us at: (614) 722-3273

Email Liubov V. Gushchina, MSc, PhD

Center for Gene Therapy700 Children’s DriveColumbus, OH 43205 (map)

Learn more about Liubov V. Gushchina

Research

Lab(s)

Center for Gene Therapy

Dr. Gushchina pursued her doctorate in Molecular Biology at the Institute of Protein Research of the Russian Academy of Science, where she developed skills in proteomics, molecular biology, biochemistry and biophysics and worked to advance understandings of protein folding and how to manipulate protein structures to enable the creation of novel therapeutics. During her postdoctoral training at The Ohio State University under the supervision of Noah Weisleder, PhD, and in collaboration with Ling-Qun Hu, MD, Dr. Gushchina developed an effective approach to prepare pluripotent stem cells (PSCs) for implantation to treat myocardial infarction and other degenerative diseases. She also investigated the role of tripartite motif (TRIM) family proteins in facilitating membrane repair capacity in striated muscle cells and lung cell regeneration after injury, work that led to the development of the MG53 protein-based therapy to treat limb-girdle muscular dystrophy type R2 (LGMDR2 or LGMD2B/dysferlinopathy) and TRIM family constructs for adeno-associated virus vector-based gene therapy treatments. As a Research Scientist in the lab of Kevin Flanigan, MD, at the Center for Gene Therapy at Nationwide Children’s Hospital, Dr. Gushchina developed a U7snRNA-based exon skipping platform to treat Duchenne Muscular Dystrophy (DMD) as well as gene replacement therapy for Limb-Girdle Muscular Dystrophy type R7 (LGMDR7). Publications

                  Gushchina LV, Vetter TA, Frair EC, Bradley AJ, Grounds KM, Lay JW, Huang N, Suhaiba A, Schnell FJ, Hanson G, Simmons TR, Wein N, Flanigan KM. Systemic PPMO-mediated dystrophin expression in the Dup2 mouse model of Duchenne muscular dystrophy. Mol Ther Nucleic Acids. 2022 Dec 13; 30: 479-492.

                


                  Wein N, Vetter TA, Vulin A, Simmons TR, Frair EC, Bradley AJ, Gushchina LV, Almeida CF, Huang N, Lesman D, Rajakumar D, Weiss RB, Flanigan KM. Systemic delivery of an AAV9 exon-skipping vector significantly improves or prevents features of Duchenne muscular dystrophy in the Dup2 mouse. Mol Ther Methods Clin Dev. 2022 Sep 8; 26: 279-293.

                


                  Wein N, Dunn DM, Waldrop MA, Gushchina LV, Frair EC, Weiss RB, Flanigan KM. Absence of Significant Off-Target Splicing Variation with a U7snRNA Vector Targeting DMD Exon 2 Duplications. Hum Gene Ther. 2021 Nov; 32: 1346-1359.

                


                  Gushchina LV, Frair EC, Rohan N, Bradley AJ, Simmons TR, Chavan HD, Chou HJ, Eggers M, Waldrop MA, Wein N, Flanigan KM. Lack of Toxicity in Nonhuman Primates Receiving Clinically Relevant Doses of an AAV9.U7snRNA Vector Designed to Induce DMD Exon 2 Skipping. Hum Gene Ther. 2021 Sep; 32: 882-894.

                


                  Gushchina LV, Kwiatkowski TA, Bhattacharya S, Weisleder NL. Conserved structural and functional aspects of the tripartite motif gene family point towards therapeutic applications in multiple diseases. Pharmacol Ther. 2018 May; 185: 12-25.

                


                  Gushchina LV, Bhattacharya S, McElhanon KE, Choi JH, Manring H, Beck EX, Alloush J, Weisleder N. Treatment with Recombinant Human MG53 Protein Increases Membrane Integrity in a Mouse Model of Limb Girdle Muscular Dystrophy 2B. Mol Ther. 2017 Oct 4; 25: 2360-2371.

View More Publications

Biography

Liubov V. Gushchina, MSc, PhD, is a Principal Investigator in the Center for Gene Therapy at the Abigail Wexner Research Institute at Nationwide Children’s Hospital, and Research Assistant Professor in the Department of Pediatrics at the Ohio State University College of Medicine. Dr. Gushchina is an experienced biochemist, molecular biologist and gene therapy specialist.

Academic and Clinical Areas

Center for Gene Therapy

Principal Investigator

Primary Department

Center for Gene Therapy

Awards, Honors & Organizations

Elsevier Prizes for Best Oral or Poster Presentation, 26th International Annual Congress of the World Muscle Society (WMS), 2021 Best Poster, The Dorothy M. Davis Heart & Lung Research Institute, The Ohio State University, USA, 2016 AHA Postdoctoral Fellowship Award, The American Heart Association (Great Rivers Affiliate), USA, 2016 Distinguished Post-Doctoral Award, The Dorothy M. Davis Heart & Lung Research Institute, The Ohio State University, USA, 2014 Muscle Group Postdoctoral Fellowship Award, The Internal Muscle Health and Neuromuscular Disorders Program, NCH/OSU, USA, 2014 Official Thanks, Governor of Moscow Region, Russia, 2011 Grant, Young Scientists of President of the Russian Federation, Russia, 2011 Short-Term Fellowship of European Molecular Biology Organization (EMBO), The Institute for Biophysical Chemistry at the Goethe University in Frankfurt am Main, Germany, 2010 Award for Young Scientists for the Best Research, Institute of Protein Research, RAS, Russia, 2009 Youth Travel Fund of Federation of European Biochemical Societies (FEBS), The FEBS Workshop “Protein Modules and Networks in Health and Disease”, Austria, 2009 Youth Travel Fund of Federation of European Biochemical Societies (FEBS), The FEBS Workshop “The Biology of Modular Protein Domains”, Austria, 2007, 2007 Youth Travel Fund of Federation of European Biochemical Societies (FEBS), The FEBS Advanced Course “Advanced Methods in Macromolecular Crystallization II”, Czech Republic, 2006 Member, World Muscle Society (WMS), 2019 - Present Member, American Society of Gene & Cell Therapy (ASGCT), 2019 - Present Member, National Center for Faculty Development and Diversity, 2017 - Present Member, Sigma Xi, 2016 - 2017 International Committee Member, OSU Postdoc Association (PDA), 2015 - Present Member, American Physiological Society (APS), 2015 - 2018 Member, Federation of European Biochemical Societies (FEBS) (Moscow Branch), 2013 - Present Member, American Heart Association (AHA), 2012 - Present Member, American Society for Nutrition (ANS), 2012 - 2016

Education

Post Doctoral

The Ohio State University

Date Completed: 06/30/2017

Graduate School

Institute of Protein Research of the Russian Academy of Science

Date Completed: 03/26/2009

Undergraduate School

M. V. Lomonosov Moscow State University

Date Completed: 06/21/2005

Professional Experience

2017 - 2022 Nationwide Children’s Hospital, Research Scientist/Sr. Research Scientist2011 - 2017 The Ohio State University, Postdoctoral Scientist2010 - 2010 Institute of Biophysical Chemistry, Goethe University in Frankfurt am Main, Invited Investigator

Contact Information

Center for Gene Therapy

Call us at: (614) 355-3171

Fax us at: (614) 722-3273

Email Liubov V Gushchina

                    700 Children's DriveColumbus, OH 43205 (map)

Connect with Liubov V. Gushchina

Connect on LinkedIn

Contact Information

Call us at: (614) 355-3171

Fax us at: (614) 722-3273

Email Liubov V. Gushchina, MSc, PhD

Center for Gene Therapy700 Children’s DriveColumbus, OH 43205 (map)

Learn more about Liubov V. Gushchina

Contact Information

  • Call us at:
  • (614) 355-3171
  • Fax us at:
  • (614) 722-3273
  • Email Liubov V. Gushchina, MSc, PhD
  • Center for Gene Therapy700 Children’s DriveColumbus, OH 43205 (map)

Learn more about Liubov V. Gushchina

Research

Lab(s)

Center for Gene Therapy

Dr. Gushchina pursued her doctorate in Molecular Biology at the Institute of Protein Research of the Russian Academy of Science, where she developed skills in proteomics, molecular biology, biochemistry and biophysics and worked to advance understandings of protein folding and how to manipulate protein structures to enable the creation of novel therapeutics. During her postdoctoral training at The Ohio State University under the supervision of Noah Weisleder, PhD, and in collaboration with Ling-Qun Hu, MD, Dr. Gushchina developed an effective approach to prepare pluripotent stem cells (PSCs) for implantation to treat myocardial infarction and other degenerative diseases. She also investigated the role of tripartite motif (TRIM) family proteins in facilitating membrane repair capacity in striated muscle cells and lung cell regeneration after injury, work that led to the development of the MG53 protein-based therapy to treat limb-girdle muscular dystrophy type R2 (LGMDR2 or LGMD2B/dysferlinopathy) and TRIM family constructs for adeno-associated virus vector-based gene therapy treatments. As a Research Scientist in the lab of Kevin Flanigan, MD, at the Center for Gene Therapy at Nationwide Children’s Hospital, Dr. Gushchina developed a U7snRNA-based exon skipping platform to treat Duchenne Muscular Dystrophy (DMD) as well as gene replacement therapy for Limb-Girdle Muscular Dystrophy type R7 (LGMDR7). Publications

                  Gushchina LV, Vetter TA, Frair EC, Bradley AJ, Grounds KM, Lay JW, Huang N, Suhaiba A, Schnell FJ, Hanson G, Simmons TR, Wein N, Flanigan KM. Systemic PPMO-mediated dystrophin expression in the Dup2 mouse model of Duchenne muscular dystrophy. Mol Ther Nucleic Acids. 2022 Dec 13; 30: 479-492.

                


                  Wein N, Vetter TA, Vulin A, Simmons TR, Frair EC, Bradley AJ, Gushchina LV, Almeida CF, Huang N, Lesman D, Rajakumar D, Weiss RB, Flanigan KM. Systemic delivery of an AAV9 exon-skipping vector significantly improves or prevents features of Duchenne muscular dystrophy in the Dup2 mouse. Mol Ther Methods Clin Dev. 2022 Sep 8; 26: 279-293.

                


                  Wein N, Dunn DM, Waldrop MA, Gushchina LV, Frair EC, Weiss RB, Flanigan KM. Absence of Significant Off-Target Splicing Variation with a U7snRNA Vector Targeting DMD Exon 2 Duplications. Hum Gene Ther. 2021 Nov; 32: 1346-1359.

                


                  Gushchina LV, Frair EC, Rohan N, Bradley AJ, Simmons TR, Chavan HD, Chou HJ, Eggers M, Waldrop MA, Wein N, Flanigan KM. Lack of Toxicity in Nonhuman Primates Receiving Clinically Relevant Doses of an AAV9.U7snRNA Vector Designed to Induce DMD Exon 2 Skipping. Hum Gene Ther. 2021 Sep; 32: 882-894.

                


                  Gushchina LV, Kwiatkowski TA, Bhattacharya S, Weisleder NL. Conserved structural and functional aspects of the tripartite motif gene family point towards therapeutic applications in multiple diseases. Pharmacol Ther. 2018 May; 185: 12-25.

                


                  Gushchina LV, Bhattacharya S, McElhanon KE, Choi JH, Manring H, Beck EX, Alloush J, Weisleder N. Treatment with Recombinant Human MG53 Protein Increases Membrane Integrity in a Mouse Model of Limb Girdle Muscular Dystrophy 2B. Mol Ther. 2017 Oct 4; 25: 2360-2371.

View More Publications

Research

Lab(s)

Center for Gene Therapy

Dr. Gushchina pursued her doctorate in Molecular Biology at the Institute of Protein Research of the Russian Academy of Science, where she developed skills in proteomics, molecular biology, biochemistry and biophysics and worked to advance understandings of protein folding and how to manipulate protein structures to enable the creation of novel therapeutics. During her postdoctoral training at The Ohio State University under the supervision of Noah Weisleder, PhD, and in collaboration with Ling-Qun Hu, MD, Dr. Gushchina developed an effective approach to prepare pluripotent stem cells (PSCs) for implantation to treat myocardial infarction and other degenerative diseases. She also investigated the role of tripartite motif (TRIM) family proteins in facilitating membrane repair capacity in striated muscle cells and lung cell regeneration after injury, work that led to the development of the MG53 protein-based therapy to treat limb-girdle muscular dystrophy type R2 (LGMDR2 or LGMD2B/dysferlinopathy) and TRIM family constructs for adeno-associated virus vector-based gene therapy treatments. As a Research Scientist in the lab of Kevin Flanigan, MD, at the Center for Gene Therapy at Nationwide Children’s Hospital, Dr. Gushchina developed a U7snRNA-based exon skipping platform to treat Duchenne Muscular Dystrophy (DMD) as well as gene replacement therapy for Limb-Girdle Muscular Dystrophy type R7 (LGMDR7). Publications

                  Gushchina LV, Vetter TA, Frair EC, Bradley AJ, Grounds KM, Lay JW, Huang N, Suhaiba A, Schnell FJ, Hanson G, Simmons TR, Wein N, Flanigan KM. Systemic PPMO-mediated dystrophin expression in the Dup2 mouse model of Duchenne muscular dystrophy. Mol Ther Nucleic Acids. 2022 Dec 13; 30: 479-492.

                


                  Wein N, Vetter TA, Vulin A, Simmons TR, Frair EC, Bradley AJ, Gushchina LV, Almeida CF, Huang N, Lesman D, Rajakumar D, Weiss RB, Flanigan KM. Systemic delivery of an AAV9 exon-skipping vector significantly improves or prevents features of Duchenne muscular dystrophy in the Dup2 mouse. Mol Ther Methods Clin Dev. 2022 Sep 8; 26: 279-293.

                


                  Wein N, Dunn DM, Waldrop MA, Gushchina LV, Frair EC, Weiss RB, Flanigan KM. Absence of Significant Off-Target Splicing Variation with a U7snRNA Vector Targeting DMD Exon 2 Duplications. Hum Gene Ther. 2021 Nov; 32: 1346-1359.

                


                  Gushchina LV, Frair EC, Rohan N, Bradley AJ, Simmons TR, Chavan HD, Chou HJ, Eggers M, Waldrop MA, Wein N, Flanigan KM. Lack of Toxicity in Nonhuman Primates Receiving Clinically Relevant Doses of an AAV9.U7snRNA Vector Designed to Induce DMD Exon 2 Skipping. Hum Gene Ther. 2021 Sep; 32: 882-894.

                


                  Gushchina LV, Kwiatkowski TA, Bhattacharya S, Weisleder NL. Conserved structural and functional aspects of the tripartite motif gene family point towards therapeutic applications in multiple diseases. Pharmacol Ther. 2018 May; 185: 12-25.

                


                  Gushchina LV, Bhattacharya S, McElhanon KE, Choi JH, Manring H, Beck EX, Alloush J, Weisleder N. Treatment with Recombinant Human MG53 Protein Increases Membrane Integrity in a Mouse Model of Limb Girdle Muscular Dystrophy 2B. Mol Ther. 2017 Oct 4; 25: 2360-2371.

View More Publications

Research

Lab(s)

Center for Gene Therapy

Dr. Gushchina pursued her doctorate in Molecular Biology at the Institute of Protein Research of the Russian Academy of Science, where she developed skills in proteomics, molecular biology, biochemistry and biophysics and worked to advance understandings of protein folding and how to manipulate protein structures to enable the creation of novel therapeutics. During her postdoctoral training at The Ohio State University under the supervision of Noah Weisleder, PhD, and in collaboration with Ling-Qun Hu, MD, Dr. Gushchina developed an effective approach to prepare pluripotent stem cells (PSCs) for implantation to treat myocardial infarction and other degenerative diseases. She also investigated the role of tripartite motif (TRIM) family proteins in facilitating membrane repair capacity in striated muscle cells and lung cell regeneration after injury, work that led to the development of the MG53 protein-based therapy to treat limb-girdle muscular dystrophy type R2 (LGMDR2 or LGMD2B/dysferlinopathy) and TRIM family constructs for adeno-associated virus vector-based gene therapy treatments. As a Research Scientist in the lab of Kevin Flanigan, MD, at the Center for Gene Therapy at Nationwide Children’s Hospital, Dr. Gushchina developed a U7snRNA-based exon skipping platform to treat Duchenne Muscular Dystrophy (DMD) as well as gene replacement therapy for Limb-Girdle Muscular Dystrophy type R7 (LGMDR7). Publications

                  Gushchina LV, Vetter TA, Frair EC, Bradley AJ, Grounds KM, Lay JW, Huang N, Suhaiba A, Schnell FJ, Hanson G, Simmons TR, Wein N, Flanigan KM. Systemic PPMO-mediated dystrophin expression in the Dup2 mouse model of Duchenne muscular dystrophy. Mol Ther Nucleic Acids. 2022 Dec 13; 30: 479-492.

                


                  Wein N, Vetter TA, Vulin A, Simmons TR, Frair EC, Bradley AJ, Gushchina LV, Almeida CF, Huang N, Lesman D, Rajakumar D, Weiss RB, Flanigan KM. Systemic delivery of an AAV9 exon-skipping vector significantly improves or prevents features of Duchenne muscular dystrophy in the Dup2 mouse. Mol Ther Methods Clin Dev. 2022 Sep 8; 26: 279-293.

                


                  Wein N, Dunn DM, Waldrop MA, Gushchina LV, Frair EC, Weiss RB, Flanigan KM. Absence of Significant Off-Target Splicing Variation with a U7snRNA Vector Targeting DMD Exon 2 Duplications. Hum Gene Ther. 2021 Nov; 32: 1346-1359.

                


                  Gushchina LV, Frair EC, Rohan N, Bradley AJ, Simmons TR, Chavan HD, Chou HJ, Eggers M, Waldrop MA, Wein N, Flanigan KM. Lack of Toxicity in Nonhuman Primates Receiving Clinically Relevant Doses of an AAV9.U7snRNA Vector Designed to Induce DMD Exon 2 Skipping. Hum Gene Ther. 2021 Sep; 32: 882-894.

                


                  Gushchina LV, Kwiatkowski TA, Bhattacharya S, Weisleder NL. Conserved structural and functional aspects of the tripartite motif gene family point towards therapeutic applications in multiple diseases. Pharmacol Ther. 2018 May; 185: 12-25.

                


                  Gushchina LV, Bhattacharya S, McElhanon KE, Choi JH, Manring H, Beck EX, Alloush J, Weisleder N. Treatment with Recombinant Human MG53 Protein Increases Membrane Integrity in a Mouse Model of Limb Girdle Muscular Dystrophy 2B. Mol Ther. 2017 Oct 4; 25: 2360-2371.

View More Publications

Lab(s)

Center for Gene Therapy

Dr. Gushchina pursued her doctorate in Molecular Biology at the Institute of Protein Research of the Russian Academy of Science, where she developed skills in proteomics, molecular biology, biochemistry and biophysics and worked to advance understandings of protein folding and how to manipulate protein structures to enable the creation of novel therapeutics. During her postdoctoral training at The Ohio State University under the supervision of Noah Weisleder, PhD, and in collaboration with Ling-Qun Hu, MD, Dr. Gushchina developed an effective approach to prepare pluripotent stem cells (PSCs) for implantation to treat myocardial infarction and other degenerative diseases. She also investigated the role of tripartite motif (TRIM) family proteins in facilitating membrane repair capacity in striated muscle cells and lung cell regeneration after injury, work that led to the development of the MG53 protein-based therapy to treat limb-girdle muscular dystrophy type R2 (LGMDR2 or LGMD2B/dysferlinopathy) and TRIM family constructs for adeno-associated virus vector-based gene therapy treatments. As a Research Scientist in the lab of Kevin Flanigan, MD, at the Center for Gene Therapy at Nationwide Children’s Hospital, Dr. Gushchina developed a U7snRNA-based exon skipping platform to treat Duchenne Muscular Dystrophy (DMD) as well as gene replacement therapy for Limb-Girdle Muscular Dystrophy type R7 (LGMDR7). Publications

                  Gushchina LV, Vetter TA, Frair EC, Bradley AJ, Grounds KM, Lay JW, Huang N, Suhaiba A, Schnell FJ, Hanson G, Simmons TR, Wein N, Flanigan KM. Systemic PPMO-mediated dystrophin expression in the Dup2 mouse model of Duchenne muscular dystrophy. Mol Ther Nucleic Acids. 2022 Dec 13; 30: 479-492.

                


                  Wein N, Vetter TA, Vulin A, Simmons TR, Frair EC, Bradley AJ, Gushchina LV, Almeida CF, Huang N, Lesman D, Rajakumar D, Weiss RB, Flanigan KM. Systemic delivery of an AAV9 exon-skipping vector significantly improves or prevents features of Duchenne muscular dystrophy in the Dup2 mouse. Mol Ther Methods Clin Dev. 2022 Sep 8; 26: 279-293.

                


                  Wein N, Dunn DM, Waldrop MA, Gushchina LV, Frair EC, Weiss RB, Flanigan KM. Absence of Significant Off-Target Splicing Variation with a U7snRNA Vector Targeting DMD Exon 2 Duplications. Hum Gene Ther. 2021 Nov; 32: 1346-1359.

                


                  Gushchina LV, Frair EC, Rohan N, Bradley AJ, Simmons TR, Chavan HD, Chou HJ, Eggers M, Waldrop MA, Wein N, Flanigan KM. Lack of Toxicity in Nonhuman Primates Receiving Clinically Relevant Doses of an AAV9.U7snRNA Vector Designed to Induce DMD Exon 2 Skipping. Hum Gene Ther. 2021 Sep; 32: 882-894.

                


                  Gushchina LV, Kwiatkowski TA, Bhattacharya S, Weisleder NL. Conserved structural and functional aspects of the tripartite motif gene family point towards therapeutic applications in multiple diseases. Pharmacol Ther. 2018 May; 185: 12-25.

                


                  Gushchina LV, Bhattacharya S, McElhanon KE, Choi JH, Manring H, Beck EX, Alloush J, Weisleder N. Treatment with Recombinant Human MG53 Protein Increases Membrane Integrity in a Mouse Model of Limb Girdle Muscular Dystrophy 2B. Mol Ther. 2017 Oct 4; 25: 2360-2371.

View More Publications

Lab(s)

Center for Gene Therapy

Dr. Gushchina pursued her doctorate in Molecular Biology at the Institute of Protein Research of the Russian Academy of Science, where she developed skills in proteomics, molecular biology, biochemistry and biophysics and worked to advance understandings of protein folding and how to manipulate protein structures to enable the creation of novel therapeutics. During her postdoctoral training at The Ohio State University under the supervision of Noah Weisleder, PhD, and in collaboration with Ling-Qun Hu, MD, Dr. Gushchina developed an effective approach to prepare pluripotent stem cells (PSCs) for implantation to treat myocardial infarction and other degenerative diseases. She also investigated the role of tripartite motif (TRIM) family proteins in facilitating membrane repair capacity in striated muscle cells and lung cell regeneration after injury, work that led to the development of the MG53 protein-based therapy to treat limb-girdle muscular dystrophy type R2 (LGMDR2 or LGMD2B/dysferlinopathy) and TRIM family constructs for adeno-associated virus vector-based gene therapy treatments. As a Research Scientist in the lab of Kevin Flanigan, MD, at the Center for Gene Therapy at Nationwide Children’s Hospital, Dr. Gushchina developed a U7snRNA-based exon skipping platform to treat Duchenne Muscular Dystrophy (DMD) as well as gene replacement therapy for Limb-Girdle Muscular Dystrophy type R7 (LGMDR7).

Lab(s)

Center for Gene Therapy

  • Center for Gene Therapy

                    Gushchina LV, Vetter TA, Frair EC, Bradley AJ, Grounds KM, Lay JW, Huang N, Suhaiba A, Schnell FJ, Hanson G, Simmons TR, Wein N, Flanigan KM. Systemic PPMO-mediated dystrophin expression in the Dup2 mouse model of Duchenne muscular dystrophy. Mol Ther Nucleic Acids. 2022 Dec 13; 30: 479-492.



                Wein N, Vetter TA, Vulin A, Simmons TR, Frair EC, Bradley AJ, Gushchina LV, Almeida CF, Huang N, Lesman D, Rajakumar D, Weiss RB, Flanigan KM. Systemic delivery of an AAV9 exon-skipping vector significantly improves or prevents features of Duchenne muscular dystrophy in the Dup2 mouse. Mol Ther Methods Clin Dev. 2022 Sep 8; 26: 279-293.



                Wein N, Dunn DM, Waldrop MA, Gushchina LV, Frair EC, Weiss RB, Flanigan KM. Absence of Significant Off-Target Splicing Variation with a U7snRNA Vector Targeting DMD Exon 2 Duplications. Hum Gene Ther. 2021 Nov; 32: 1346-1359.



                Gushchina LV, Frair EC, Rohan N, Bradley AJ, Simmons TR, Chavan HD, Chou HJ, Eggers M, Waldrop MA, Wein N, Flanigan KM. Lack of Toxicity in Nonhuman Primates Receiving Clinically Relevant Doses of an AAV9.U7snRNA Vector Designed to Induce DMD Exon 2 Skipping. Hum Gene Ther. 2021 Sep; 32: 882-894.



                Gushchina LV, Kwiatkowski TA, Bhattacharya S, Weisleder NL. Conserved structural and functional aspects of the tripartite motif gene family point towards therapeutic applications in multiple diseases. Pharmacol Ther. 2018 May; 185: 12-25.



                Gushchina LV, Bhattacharya S, McElhanon KE, Choi JH, Manring H, Beck EX, Alloush J, Weisleder N. Treatment with Recombinant Human MG53 Protein Increases Membrane Integrity in a Mouse Model of Limb Girdle Muscular Dystrophy 2B. Mol Ther. 2017 Oct 4; 25: 2360-2371.

View More Publications

  • Gushchina LV, Vetter TA, Frair EC, Bradley AJ, Grounds KM, Lay JW, Huang N, Suhaiba A, Schnell FJ, Hanson G, Simmons TR, Wein N, Flanigan KM. Systemic PPMO-mediated dystrophin expression in the Dup2 mouse model of Duchenne muscular dystrophy. Mol Ther Nucleic Acids. 2022 Dec 13; 30: 479-492.
  • Wein N, Vetter TA, Vulin A, Simmons TR, Frair EC, Bradley AJ, Gushchina LV, Almeida CF, Huang N, Lesman D, Rajakumar D, Weiss RB, Flanigan KM. Systemic delivery of an AAV9 exon-skipping vector significantly improves or prevents features of Duchenne muscular dystrophy in the Dup2 mouse. Mol Ther Methods Clin Dev. 2022 Sep 8; 26: 279-293.
  • Wein N, Dunn DM, Waldrop MA, Gushchina LV, Frair EC, Weiss RB, Flanigan KM. Absence of Significant Off-Target Splicing Variation with a U7snRNA Vector Targeting DMD Exon 2 Duplications. Hum Gene Ther. 2021 Nov; 32: 1346-1359.
  • Gushchina LV, Frair EC, Rohan N, Bradley AJ, Simmons TR, Chavan HD, Chou HJ, Eggers M, Waldrop MA, Wein N, Flanigan KM. Lack of Toxicity in Nonhuman Primates Receiving Clinically Relevant Doses of an AAV9.U7snRNA Vector Designed to Induce DMD Exon 2 Skipping. Hum Gene Ther. 2021 Sep; 32: 882-894.
  • Gushchina LV, Kwiatkowski TA, Bhattacharya S, Weisleder NL. Conserved structural and functional aspects of the tripartite motif gene family point towards therapeutic applications in multiple diseases. Pharmacol Ther. 2018 May; 185: 12-25.
  • Gushchina LV, Bhattacharya S, McElhanon KE, Choi JH, Manring H, Beck EX, Alloush J, Weisleder N. Treatment with Recombinant Human MG53 Protein Increases Membrane Integrity in a Mouse Model of Limb Girdle Muscular Dystrophy 2B. Mol Ther. 2017 Oct 4; 25: 2360-2371.

Biography

Liubov V. Gushchina, MSc, PhD, is a Principal Investigator in the Center for Gene Therapy at the Abigail Wexner Research Institute at Nationwide Children’s Hospital, and Research Assistant Professor in the Department of Pediatrics at the Ohio State University College of Medicine. Dr. Gushchina is an experienced biochemist, molecular biologist and gene therapy specialist.

Biography

Liubov V. Gushchina, MSc, PhD, is a Principal Investigator in the Center for Gene Therapy at the Abigail Wexner Research Institute at Nationwide Children’s Hospital, and Research Assistant Professor in the Department of Pediatrics at the Ohio State University College of Medicine. Dr. Gushchina is an experienced biochemist, molecular biologist and gene therapy specialist.

Biography

Liubov V. Gushchina, MSc, PhD, is a Principal Investigator in the Center for Gene Therapy at the Abigail Wexner Research Institute at Nationwide Children’s Hospital, and Research Assistant Professor in the Department of Pediatrics at the Ohio State University College of Medicine. Dr. Gushchina is an experienced biochemist, molecular biologist and gene therapy specialist.

Liubov V. Gushchina, MSc, PhD, is a Principal Investigator in the Center for Gene Therapy at the Abigail Wexner Research Institute at Nationwide Children’s Hospital, and Research Assistant Professor in the Department of Pediatrics at the Ohio State University College of Medicine. Dr. Gushchina is an experienced biochemist, molecular biologist and gene therapy specialist.

Liubov V. Gushchina, MSc, PhD, is a Principal Investigator in the Center for Gene Therapy at the Abigail Wexner Research Institute at Nationwide Children’s Hospital, and Research Assistant Professor in the Department of Pediatrics at the Ohio State University College of Medicine. Dr. Gushchina is an experienced biochemist, molecular biologist and gene therapy specialist.

Academic and Clinical Areas

Center for Gene Therapy

Principal Investigator

Primary Department

Center for Gene Therapy

Academic and Clinical Areas

Center for Gene Therapy

Principal Investigator

Primary Department

Center for Gene Therapy

Academic and Clinical Areas

Center for Gene Therapy

Principal Investigator

Primary Department

Center for Gene Therapy

Center for Gene Therapy

Principal Investigator

Primary Department

Center for Gene Therapy

  • Center for Gene Therapy
  • Principal Investigator
  • Primary Department
  • Center for Gene Therapy

Awards, Honors & Organizations

Elsevier Prizes for Best Oral or Poster Presentation, 26th International Annual Congress of the World Muscle Society (WMS), 2021 Best Poster, The Dorothy M. Davis Heart & Lung Research Institute, The Ohio State University, USA, 2016 AHA Postdoctoral Fellowship Award, The American Heart Association (Great Rivers Affiliate), USA, 2016 Distinguished Post-Doctoral Award, The Dorothy M. Davis Heart & Lung Research Institute, The Ohio State University, USA, 2014 Muscle Group Postdoctoral Fellowship Award, The Internal Muscle Health and Neuromuscular Disorders Program, NCH/OSU, USA, 2014 Official Thanks, Governor of Moscow Region, Russia, 2011 Grant, Young Scientists of President of the Russian Federation, Russia, 2011 Short-Term Fellowship of European Molecular Biology Organization (EMBO), The Institute for Biophysical Chemistry at the Goethe University in Frankfurt am Main, Germany, 2010 Award for Young Scientists for the Best Research, Institute of Protein Research, RAS, Russia, 2009 Youth Travel Fund of Federation of European Biochemical Societies (FEBS), The FEBS Workshop “Protein Modules and Networks in Health and Disease”, Austria, 2009 Youth Travel Fund of Federation of European Biochemical Societies (FEBS), The FEBS Workshop “The Biology of Modular Protein Domains”, Austria, 2007, 2007 Youth Travel Fund of Federation of European Biochemical Societies (FEBS), The FEBS Advanced Course “Advanced Methods in Macromolecular Crystallization II”, Czech Republic, 2006 Member, World Muscle Society (WMS), 2019 - Present Member, American Society of Gene & Cell Therapy (ASGCT), 2019 - Present Member, National Center for Faculty Development and Diversity, 2017 - Present Member, Sigma Xi, 2016 - 2017 International Committee Member, OSU Postdoc Association (PDA), 2015 - Present Member, American Physiological Society (APS), 2015 - 2018 Member, Federation of European Biochemical Societies (FEBS) (Moscow Branch), 2013 - Present Member, American Heart Association (AHA), 2012 - Present Member, American Society for Nutrition (ANS), 2012 - 2016

Awards, Honors & Organizations

Elsevier Prizes for Best Oral or Poster Presentation, 26th International Annual Congress of the World Muscle Society (WMS), 2021 Best Poster, The Dorothy M. Davis Heart & Lung Research Institute, The Ohio State University, USA, 2016 AHA Postdoctoral Fellowship Award, The American Heart Association (Great Rivers Affiliate), USA, 2016 Distinguished Post-Doctoral Award, The Dorothy M. Davis Heart & Lung Research Institute, The Ohio State University, USA, 2014 Muscle Group Postdoctoral Fellowship Award, The Internal Muscle Health and Neuromuscular Disorders Program, NCH/OSU, USA, 2014 Official Thanks, Governor of Moscow Region, Russia, 2011 Grant, Young Scientists of President of the Russian Federation, Russia, 2011 Short-Term Fellowship of European Molecular Biology Organization (EMBO), The Institute for Biophysical Chemistry at the Goethe University in Frankfurt am Main, Germany, 2010 Award for Young Scientists for the Best Research, Institute of Protein Research, RAS, Russia, 2009 Youth Travel Fund of Federation of European Biochemical Societies (FEBS), The FEBS Workshop “Protein Modules and Networks in Health and Disease”, Austria, 2009 Youth Travel Fund of Federation of European Biochemical Societies (FEBS), The FEBS Workshop “The Biology of Modular Protein Domains”, Austria, 2007, 2007 Youth Travel Fund of Federation of European Biochemical Societies (FEBS), The FEBS Advanced Course “Advanced Methods in Macromolecular Crystallization II”, Czech Republic, 2006 Member, World Muscle Society (WMS), 2019 - Present Member, American Society of Gene & Cell Therapy (ASGCT), 2019 - Present Member, National Center for Faculty Development and Diversity, 2017 - Present Member, Sigma Xi, 2016 - 2017 International Committee Member, OSU Postdoc Association (PDA), 2015 - Present Member, American Physiological Society (APS), 2015 - 2018 Member, Federation of European Biochemical Societies (FEBS) (Moscow Branch), 2013 - Present Member, American Heart Association (AHA), 2012 - Present Member, American Society for Nutrition (ANS), 2012 - 2016

Awards, Honors & Organizations

Elsevier Prizes for Best Oral or Poster Presentation, 26th International Annual Congress of the World Muscle Society (WMS), 2021 Best Poster, The Dorothy M. Davis Heart & Lung Research Institute, The Ohio State University, USA, 2016 AHA Postdoctoral Fellowship Award, The American Heart Association (Great Rivers Affiliate), USA, 2016 Distinguished Post-Doctoral Award, The Dorothy M. Davis Heart & Lung Research Institute, The Ohio State University, USA, 2014 Muscle Group Postdoctoral Fellowship Award, The Internal Muscle Health and Neuromuscular Disorders Program, NCH/OSU, USA, 2014 Official Thanks, Governor of Moscow Region, Russia, 2011 Grant, Young Scientists of President of the Russian Federation, Russia, 2011 Short-Term Fellowship of European Molecular Biology Organization (EMBO), The Institute for Biophysical Chemistry at the Goethe University in Frankfurt am Main, Germany, 2010 Award for Young Scientists for the Best Research, Institute of Protein Research, RAS, Russia, 2009 Youth Travel Fund of Federation of European Biochemical Societies (FEBS), The FEBS Workshop “Protein Modules and Networks in Health and Disease”, Austria, 2009 Youth Travel Fund of Federation of European Biochemical Societies (FEBS), The FEBS Workshop “The Biology of Modular Protein Domains”, Austria, 2007, 2007 Youth Travel Fund of Federation of European Biochemical Societies (FEBS), The FEBS Advanced Course “Advanced Methods in Macromolecular Crystallization II”, Czech Republic, 2006 Member, World Muscle Society (WMS), 2019 - Present Member, American Society of Gene & Cell Therapy (ASGCT), 2019 - Present Member, National Center for Faculty Development and Diversity, 2017 - Present Member, Sigma Xi, 2016 - 2017 International Committee Member, OSU Postdoc Association (PDA), 2015 - Present Member, American Physiological Society (APS), 2015 - 2018 Member, Federation of European Biochemical Societies (FEBS) (Moscow Branch), 2013 - Present Member, American Heart Association (AHA), 2012 - Present Member, American Society for Nutrition (ANS), 2012 - 2016

Elsevier Prizes for Best Oral or Poster Presentation, 26th International Annual Congress of the World Muscle Society (WMS), 2021 Best Poster, The Dorothy M. Davis Heart & Lung Research Institute, The Ohio State University, USA, 2016 AHA Postdoctoral Fellowship Award, The American Heart Association (Great Rivers Affiliate), USA, 2016 Distinguished Post-Doctoral Award, The Dorothy M. Davis Heart & Lung Research Institute, The Ohio State University, USA, 2014 Muscle Group Postdoctoral Fellowship Award, The Internal Muscle Health and Neuromuscular Disorders Program, NCH/OSU, USA, 2014 Official Thanks, Governor of Moscow Region, Russia, 2011 Grant, Young Scientists of President of the Russian Federation, Russia, 2011 Short-Term Fellowship of European Molecular Biology Organization (EMBO), The Institute for Biophysical Chemistry at the Goethe University in Frankfurt am Main, Germany, 2010 Award for Young Scientists for the Best Research, Institute of Protein Research, RAS, Russia, 2009 Youth Travel Fund of Federation of European Biochemical Societies (FEBS), The FEBS Workshop “Protein Modules and Networks in Health and Disease”, Austria, 2009 Youth Travel Fund of Federation of European Biochemical Societies (FEBS), The FEBS Workshop “The Biology of Modular Protein Domains”, Austria, 2007, 2007 Youth Travel Fund of Federation of European Biochemical Societies (FEBS), The FEBS Advanced Course “Advanced Methods in Macromolecular Crystallization II”, Czech Republic, 2006 Member, World Muscle Society (WMS), 2019 - Present Member, American Society of Gene & Cell Therapy (ASGCT), 2019 - Present Member, National Center for Faculty Development and Diversity, 2017 - Present Member, Sigma Xi, 2016 - 2017 International Committee Member, OSU Postdoc Association (PDA), 2015 - Present Member, American Physiological Society (APS), 2015 - 2018 Member, Federation of European Biochemical Societies (FEBS) (Moscow Branch), 2013 - Present Member, American Heart Association (AHA), 2012 - Present Member, American Society for Nutrition (ANS), 2012 - 2016

  • Elsevier Prizes for Best Oral or Poster Presentation, 26th International Annual Congress of the World Muscle Society (WMS), 2021
  • Best Poster, The Dorothy M. Davis Heart & Lung Research Institute, The Ohio State University, USA, 2016
  • AHA Postdoctoral Fellowship Award, The American Heart Association (Great Rivers Affiliate), USA, 2016
  • Distinguished Post-Doctoral Award, The Dorothy M. Davis Heart & Lung Research Institute, The Ohio State University, USA, 2014
  • Muscle Group Postdoctoral Fellowship Award, The Internal Muscle Health and Neuromuscular Disorders Program, NCH/OSU, USA, 2014
  • Official Thanks, Governor of Moscow Region, Russia, 2011
  • Grant, Young Scientists of President of the Russian Federation, Russia, 2011
  • Short-Term Fellowship of European Molecular Biology Organization (EMBO), The Institute for Biophysical Chemistry at the Goethe University in Frankfurt am Main, Germany, 2010
  • Award for Young Scientists for the Best Research, Institute of Protein Research, RAS, Russia, 2009
  • Youth Travel Fund of Federation of European Biochemical Societies (FEBS), The FEBS Workshop “Protein Modules and Networks in Health and Disease”, Austria, 2009
  • Youth Travel Fund of Federation of European Biochemical Societies (FEBS), The FEBS Workshop “The Biology of Modular Protein Domains”, Austria, 2007, 2007
  • Youth Travel Fund of Federation of European Biochemical Societies (FEBS), The FEBS Advanced Course “Advanced Methods in Macromolecular Crystallization II”, Czech Republic, 2006
  • Member, World Muscle Society (WMS), 2019 - Present
  • Member, American Society of Gene & Cell Therapy (ASGCT), 2019 - Present
  • Member, National Center for Faculty Development and Diversity, 2017 - Present
  • Member, Sigma Xi, 2016 - 2017
  • International Committee Member, OSU Postdoc Association (PDA), 2015 - Present
  • Member, American Physiological Society (APS), 2015 - 2018
  • Member, Federation of European Biochemical Societies (FEBS) (Moscow Branch), 2013 - Present
  • Member, American Heart Association (AHA), 2012 - Present
  • Member, American Society for Nutrition (ANS), 2012 - 2016

Education

Post Doctoral

The Ohio State University

Date Completed: 06/30/2017

Graduate School

Institute of Protein Research of the Russian Academy of Science

Date Completed: 03/26/2009

Undergraduate School

M. V. Lomonosov Moscow State University

Date Completed: 06/21/2005

Education

Post Doctoral

The Ohio State University

Date Completed: 06/30/2017

Graduate School

Institute of Protein Research of the Russian Academy of Science

Date Completed: 03/26/2009

Undergraduate School

M. V. Lomonosov Moscow State University

Date Completed: 06/21/2005

Education

Post Doctoral

The Ohio State University

Date Completed: 06/30/2017

Graduate School

Institute of Protein Research of the Russian Academy of Science

Date Completed: 03/26/2009

Undergraduate School

M. V. Lomonosov Moscow State University

Date Completed: 06/21/2005

Post Doctoral

The Ohio State University

Date Completed: 06/30/2017

Graduate School

Institute of Protein Research of the Russian Academy of Science

Date Completed: 03/26/2009

Undergraduate School

M. V. Lomonosov Moscow State University

Date Completed: 06/21/2005

Post Doctoral

The Ohio State University

Date Completed: 06/30/2017

Graduate School

Institute of Protein Research of the Russian Academy of Science

Date Completed: 03/26/2009

Undergraduate School

M. V. Lomonosov Moscow State University

Date Completed: 06/21/2005

Professional Experience

2017 - 2022 Nationwide Children’s Hospital, Research Scientist/Sr. Research Scientist2011 - 2017 The Ohio State University, Postdoctoral Scientist2010 - 2010 Institute of Biophysical Chemistry, Goethe University in Frankfurt am Main, Invited Investigator

Professional Experience

2017 - 2022 Nationwide Children’s Hospital, Research Scientist/Sr. Research Scientist2011 - 2017 The Ohio State University, Postdoctoral Scientist2010 - 2010 Institute of Biophysical Chemistry, Goethe University in Frankfurt am Main, Invited Investigator

Professional Experience

2017 - 2022 Nationwide Children’s Hospital, Research Scientist/Sr. Research Scientist2011 - 2017 The Ohio State University, Postdoctoral Scientist2010 - 2010 Institute of Biophysical Chemistry, Goethe University in Frankfurt am Main, Invited Investigator

2017 - 2022 Nationwide Children’s Hospital, Research Scientist/Sr. Research Scientist2011 - 2017 The Ohio State University, Postdoctoral Scientist2010 - 2010 Institute of Biophysical Chemistry, Goethe University in Frankfurt am Main, Invited Investigator

2017 - 2022 Nationwide Children’s Hospital, Research Scientist/Sr. Research Scientist

Contact Information

Center for Gene Therapy

Call us at: (614) 355-3171

Fax us at: (614) 722-3273

Email Liubov V Gushchina

                    700 Children's DriveColumbus, OH 43205 (map)

Contact Information

Center for Gene Therapy

Call us at: (614) 355-3171

Fax us at: (614) 722-3273

Email Liubov V Gushchina

                    700 Children's DriveColumbus, OH 43205 (map)

Contact Information

Center for Gene Therapy

Call us at: (614) 355-3171

Fax us at: (614) 722-3273

Email Liubov V Gushchina

                    700 Children's DriveColumbus, OH 43205 (map)

Center for Gene Therapy

Call us at: (614) 355-3171

Fax us at: (614) 722-3273

Email Liubov V Gushchina

                    700 Children's DriveColumbus, OH 43205 (map)

Call us at: (614) 355-3171

Fax us at: (614) 722-3273

Email Liubov V Gushchina

                    700 Children's DriveColumbus, OH 43205 (map)

Call us at: (614) 355-3171

Fax us at: (614) 722-3273

Email Liubov V Gushchina

                    700 Children's DriveColumbus, OH 43205 (map)
  • Call us at:
  • (614) 355-3171
  • Fax us at:
  • (614) 722-3273
  • Email Liubov V Gushchina
  • 700 Children’s DriveColumbus, OH 43205 (map)

Connect with Liubov V. Gushchina

Connect on LinkedIn